(2026). Neuron‐targeted 2‐deoxyglucose‐dendrimer‐rosiglitazone nanotherapy mitigates neuroinflammation and cognitive deficits in pediatric traumatic brain injury. Bioengineering & Translational Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Neuron‐targeted 2‐deoxyglucose‐dendrimer‐rosiglitazone Nanotherapy Mitigates Neuroinflammation and Cognitive Deficits in Pediatric Traumatic Brain Injury."
Bioengineering & Translational Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Neuron‐targeted 2‐deoxyglucose‐dendrimer‐rosiglitazone Nanotherapy Mitigates Neuroinflammation and Cognitive Deficits in Pediatric Traumatic Brain Injury."
Bioengineering & Translational Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.